{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:31:03Z","timestamp":1790706663016,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jaci.2023.01.012","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T04:41:44Z","timestamp":1674621704000},"page":"686-690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunodeficiency secondary to biologics"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-2098","authenticated-orcid":false,"given":"Roxane","family":"Labrosse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.01.012_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1546-0096-12-45","article-title":"Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-alpha reagents","volume":"12","author":"Yasui","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jaci.2023.01.012_bib2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2023.01.012_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.01.012_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaci.2021.03.041","article-title":"Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients","volume":"148","author":"Labrosse","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl\u00a02","key":"10.1016\/j.jaci.2023.01.012_bib5","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaci.2023.01.012_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fimmu.2015.00241","article-title":"B cells and progressive multifocal leukoencephalopathy: search for the missing link","volume":"6","author":"Durali","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.01.012_bib7","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.01.012_bib8","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaci.2023.01.012_bib9","doi-asserted-by":"crossref","first-page":"e2295","DOI":"10.1002\/rmv.2295","article-title":"Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis","volume":"32","author":"Peng","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jaci.2023.01.012_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270668","article-title":"Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: a network meta-analysis","volume":"17","author":"Godolphin","year":"2022","journal-title":"PLoS One"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:43:50Z","timestamp":1758793430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0091674923000866"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.01.012","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunodeficiency secondary to biologics","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}